Our initial disease target is ascites due to advanced liver cirrhosis resulting from NASH (non-alcoholic steatohepatitis), hepatitis B & C, alcoholism, or other causes. Ascites is the most common complication of advanced (“decompensated”) liver cirrhosis. It involves the excessive accumulation of fluid in the abdomen, and complications of ascites are often life-threatening.
The current standard of care has generally poor outcomes. Unfortunately, patients often have nothing hopeful to look forward to other than the possibility of a liver transplant.
We are targeting the disease pathway of ascites. Taking a new look at the mechanistic source, we are engineering a solution that is a combination of existing technology and innovative application.
We are conducting clinical trials which, if successful, could yield a breakthrough treatment for this life-threatening condition.
Alzheimer’s disease is a neuroinflammatory, neurodegenerative condition, characterized by progressive deterioration of cognitive function and loss of short-term memory and executive function.
Formal diagnosis of Alzheimer’s disease has historically been dependent on the presence of extraneuronal amyloid beta (Ab) plaques, which can only be observed at autopsy or with the aid of sophisticated radioimaging techniques.
Diagnostic methods have recently been approved that quantify Ab in peripheral blood and correlate well with imaging results, however Ab plaques can also be found in people without apparent AD symptoms, which has cast doubt about the role of Ab as the central mediator of disease pathology. The results of the pharmaceutical industry’s focus on Ab centric drug development have been disappointing.
BioVie has a different approach, which focuses on the root cause of the disease, inflammation. We are developing NE3107, which has a unique mechanism of action and pharmaceutical characteristics that could provide an opportunity to change the trajectory of the burden of Alzheimer’s care and improve the lives of millions Alzheimer’s patients and their caregivers.
Parkinson’s is a progressive, debilitating neurologic conditions that can destroy motor kills and the ability to speak. Nearly 1 million people in the US are living with the disease and the numbers is expected to grow by 20% in the next 10 years.
We are committed to developing therapies to help people suffering from Parkinson's. BioVie is planning on advancing NE3017 in Parkinson's based on promising results from our preclinical trials.
This website contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 that involve risks, uncertainties, and assumptions that could cause BioVie’s actual results and experience to differ materially from anticipated results and expectations expressed in these forward-looking statements.